Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $463458.0.

  • Ensysce Biosciences' Accounts Payables fell 7644.52% to $463458.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $463458.0, marking a year-over-year decrease of 7644.52%. This contributed to the annual value of $1.4 million for FY2024, which is 2990.32% down from last year.
  • Latest data reveals that Ensysce Biosciences reported Accounts Payables of $463458.0 as of Q3 2025, which was down 7644.52% from $1.0 million recorded in Q2 2025.
  • Ensysce Biosciences' Accounts Payables' 5-year high stood at $3.1 million during Q2 2021, with a 5-year trough of $301104.0 in Q4 2021.
  • Moreover, its 5-year median value for Accounts Payables was $1.2 million (2022), whereas its average is $1.4 million.
  • Within the past 5 years, the most significant YoY rise in Ensysce Biosciences' Accounts Payables was 181873.58% (2021), while the steepest drop was 8254.06% (2021).
  • Quarter analysis of 5 years shows Ensysce Biosciences' Accounts Payables stood at $301104.0 in 2021, then surged by 877.67% to $2.9 million in 2022, then crashed by 34.23% to $1.9 million in 2023, then fell by 29.9% to $1.4 million in 2024, then tumbled by 65.85% to $463458.0 in 2025.
  • Its last three reported values are $463458.0 in Q3 2025, $1.0 million for Q2 2025, and $615295.0 during Q1 2025.